Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · Real-Time Price · USD
255.00
-6.08 (-2.33%)
At close: Mar 11, 2026, 4:00 PM EDT
253.60
-1.40 (-0.55%)
After-hours: Mar 11, 2026, 7:55 PM EDT
Krystal Biotech Stock Forecast
Stock Price Forecast
The 10 analysts that cover Krystal Biotech stock have a consensus rating of "Strong Buy" and an average price target of $297.6, which forecasts a 16.71% increase in the stock price over the next year. The lowest target is $176 and the highest is $371.
Price Target: $297.6 (+16.71%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Krystal Biotech stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 8 | 9 | 9 |
| Buy | 1 | 1 | 1 | 1 | 0 | 0 |
| Hold | 2 | 2 | 2 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Maintains $224 → $284 | Strong Buy | Maintains | $224 → $284 | +11.37% | Feb 25, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $336 → $371 | Strong Buy | Maintains | $336 → $371 | +45.49% | Feb 18, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $220 → $323 | Strong Buy | Maintains | $220 → $323 | +26.67% | Feb 18, 2026 |
| Jefferies | Jefferies | Strong Buy Maintains $310 → $371 | Strong Buy | Maintains | $310 → $371 | +45.49% | Feb 17, 2026 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $206 → $327 | Strong Buy | Maintains | $206 → $327 | +28.24% | Feb 2, 2026 |
Financial Forecast
Revenue This Year
548.21M
from 389.13M
Increased by 40.88%
Revenue Next Year
740.96M
from 548.21M
Increased by 35.16%
EPS This Year
7.87
from 6.84
Increased by 15.09%
EPS Next Year
11.13
from 7.87
Increased by 41.39%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 631.9M | 1.0B | |||
| Avg | 548.2M | 741.0M | |||
| Low | 439.9M | 571.1M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 62.4% | 88.1% | |||
| Avg | 40.9% | 35.2% | |||
| Low | 13.1% | 4.2% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 10.07 | 20.91 | |||
| Avg | 7.87 | 11.13 | |||
| Low | 5.66 | 6.28 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 47.2% | 165.6% | |||
| Avg | 15.1% | 41.4% | |||
| Low | -17.2% | -20.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.